$29.26
Today
as of Aug 5, 16:49 ET
Last 30 days
Recent Press Releases & News
Earnings To Watch: Genmab AS (GMAB) Q2 2026 -- GF Value Sees 47% Upside
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
TD Cowen Upgrades Genmab to Buy From Hold, Raises Price Target to $43 From $32
Overview
52-week range
$20
$35
59% of range
Avg surprise (last 3)
+24.4%
Avg reaction (last 2)
-4.4%
0% positive
Latest IV / EM
73%
EM ±12.1% · $30 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $0.15 | $0.15 | 0.0% | -51.6% | -3.0% | earnings |
| Thu Aug 7, 2025 | Jun/2025 | $0.54 | $0.39 | +38.5% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $0.31 | $0.23 | +34.8% | — | -5.7% | earnings |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | BMO | $0.37 | $0.54 | -31.5% |